We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 148

Antibody patent found valid and infringed

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 27 2014

The Court recently decided a patent infringement case dealing with antibodies. The claims at issue in AbbVie’s patent relate to the use of a human

Reply affidavits allowed when new documents introduced in responding evidence

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 9 2014

In this case, there is a partial reversal of evidence. Apotex brought a motion for leave to file reply evidence. Allergan did not oppose parts of the

Leave to amend Statement of Defence denied

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 18 2011

Shire brought a motion seeking leave to amend its Statement of Defence to add a new defence of infringement as well as a defence of failure to mitigate

Janssen-Ortho v. Apotex

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • July 20 2010

This proceeding has had a complex history

The Court of Appeal sends s.8 case back to trial judge for redetermination

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • March 26 2012

The Federal Court of Appeal (FCA) has granted Apotex’ appeal and sent a case considering s. 8 of the Patented Medicines (Notice of Compliance) Regulations (the Regulations) back to the Trial Judge for redetermination

Pfizer Canada Inc. v. Novopharm, The Minister of Health, Northwestern University and the Board of Regents for the University of Oklahoma

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • July 5 2010

In a proceeding pursuant to the Patented Medicines (Notice of Compliance) Regulations, Novopharm brought a motion seeking a Protective Order that allowed the designation of Novopharm's Notice of Allegation (NOA) as confidential

Court finds allegations in NOA to be unjustified, however dismisses application for prohibition on basis of mootness

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • November 18 2010

In this proceeding under the NOC Regulations, the Court found all of Apotex’ allegations to be unjustified

Court declares drug eligible for listing on the register of innovative drugs

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • February 13 2012

In this case, Celgene judicially reviewed a decision of the Minister of Health not to list their drug THALOMID thalidomide on the Register of Innovative Drugs (the Register

Patent refused listing on the Patent Register

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 30 2012

The Federal Court dismissed a judicial review of a decision of the Minister of Health refusing to list a patent on the Patent Register

NOC proceeding dismissed on the basis of overbreadth and a lack of sound prediction

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • February 13 2013

In this case, one claim of a patent was at issue in the proceeding. The claim related to the use of pregabalin or its racemate to treat pain. The